| Identification | Back Directory | [Name]
Goserelin acetate | [CAS]
145781-92-6 | [Synonyms]
Fertilan
Goserelin HCl
Goserelin acetate
Gosorelin Acetate
Goserelin Acteate
Goserilyn acetate
ICI-118630 acetate
Goserelin acetate/Fertilan
Goserelin?Acetate impurity
(D-SER(TBU)6,AZAGLY10)-LHRH
Goserelin acetate USP/EP/BP
[(T-BU)DSER6, (AZA)GLY10]-LH-RH
Goserelin for NMR identification
Goserelin acetate (ICI-118630 acetate)
Goserelin Acetate (100 mg) (COLD SHIPMENT REQUIRED)
PYR-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-AZAGLY-NH2
GLP-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-AZA-GLY-NH2
(D-Ser(tBu)6,Azagly10)-LHRH acetate salt
[(T-BU)DSER6, (AZA)GLY10]-LUTEINIZING HORMONE-RELEASING HORMONE
GOSERELIN HCL[PYR-HIS-TRP-SER-TYR-D-SER(T-BU)-LEU-ARG-PRO-AZAGLY-NH2]
1-9-Luteinizing hormone-releasing factor (swine), 6-(o-(1,1-dimethylethyl)-D-serine)-, 2-(aminocarbonyl)hydrazide, acetate (salt)
(2S)-1-[(2R)-2-[(2R)-2-[(2R)-3-(tert-butoxy)-2-[(2R)-2-[(2R)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-iMidazol-5-yl)-2-{[(2R)-5-oxopyrrolidin-2-yl]forMaMido}propanaMido]-3-(1H-indol-3-yl)propanaMido]propanaMido]-3-(4-hydroxyphenyl)propanaMido]propanaMido]-4-Methyl | [EINECS(EC#)]
652-995-1 | [Molecular Formula]
C59H84N18O14 | [MDL Number]
MFCD00867894 | [MOL File]
145781-92-6.mol | [Molecular Weight]
1269.41 |
| Chemical Properties | Back Directory | [Melting point ]
>190°C (dec.) | [storage temp. ]
−20°C
| [solubility ]
H2O: 20 mg/mL, clear, colorless
| [form ]
white powder
| [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
IKDXDQDKCZPQSZ-JHYYTBFNSA-N |
| Hazard Information | Back Directory | [Description]
Goserelin acetate, like leuprolide acetate, is a synthetic superagonist nonapeptide analogue of
GnRH that possesses greater potency than the natural hormone. Note that it contains D-Ser(But)
and NH-NHCONH2 in place of Gly6 and Gly10-NH2, respectively. That is, the C terminal modification simply has an NH substituting for the CH2 of Gly, and like the C-terminal
change in leuprolide acetate, this inhibits enzymatic degradation of the peptide by the
postproline carboxyamide peptidase.
Goserelin acetate is available in the form of a small, solid pellet that is administered as an SC
implant for the palliative treatment of advanced, metastatic breast cancer in pre- and
perimenopausal women or, similarly, as a palliative in advanced prostatic cancer. The rationale
for this drug's use is, as described above, its ability as a superagonist to bring the levels of
estradiol or testosterone to near castrate levels, thus slowing the progression of breast or
prostate carcinoma, respectively. Additionally, goserelin acetate is approved for use in treating
endometriosis for up to 6 months. | [Chemical Properties]
White Solid | [Uses]
Anticancer | [Uses]
injectable gonadotropin releasing hormone superagonist (GnRH agonist) or luteinizing hormone antiproliferative activity in breast, prostate and endometrial cancers | [Uses]
Synthetic peptide agonist analog of LH-RH. Antineoplastic (hormonal). | [General Description]
Goserelin acetate is a synthetic decapaptide, which is a potent analog of LHRH (luteinizing hormone releasing hormone). | [Biochem/physiol Actions]
Goserelin acetate peptide results in significant inhibition of gonadotropin release and suppresses steroidogenesis in ovaries and testis. Thus, it leads to a reduction of testosterone to castration levels and estrogen to postmenopausal levels. Therefore, this peptide is used for reducing testosterone levels in patients with locally advanced prostate cancer. | [Clinical Use]
Goserelin acetate also is used in combination with the antiandrogen flutamide for shrinking
prostate carcinoma before radiation therapy. This maximal androgen blockade combination is
used when the prostate carcinoma has been staged as locally confined to the prostate gland,
with one or both lobes as well as the seminal vesicles involved. The treatment should start 8
weeks before radiation treatment begins and be continued throughout the radiation therapy.
Furthermore, women who are to undergo hysterectomy for menorrhagia can benefit from
previous treatment with goserelin acetate, because it is able to induce endometrial thinning.
This thinning of the endometrium improves the operating environment by causing less
intrauterine bleeding, increased postoperative amenorrhea, and decreased dysmenorrhea
following surgery, which is why goserelin acetate is approved for inducing endometrial thinning
prior to a patient undergoing a hysterectomy for heavy menstrual bleeding. | [storage]
Store at -20°C |
|
|